ID

22265

Beschreibung

Trial of GM-CSF Given in Combination With Ketoconazole and Mitoxantrone in Patients With Progressive Prostate Cancer; ODM derived from: https://clinicaltrials.gov/show/NCT00447473

Link

https://clinicaltrials.gov/show/NCT00447473

Stichworte

Versionen (1)
  1. 27.05.17 27.05.17 -
Hochgeladen am

27. Mai 2017

DOI

Für eine Beantragung loggen Sie sich ein.

Lizenz

Creative Commons BY 4.0
Modell Kommentare :

Hier können Sie das Modell kommentieren. Über die Sprechblasen an den Itemgruppen und Items können Sie diese spezifisch kommentieren.

Zurück zu Modell Kommentaren
Itemgroup Kommentare für :

Item Kommentare für :

Um Formulare herunterzuladen müssen Sie angemeldet sein. Bitte loggen Sie sich ein oder registrieren Sie sich kostenlos.

Eligibility Prostatic Neoplasms NCT00447473

Englisch

Eligibility Prostatic Neoplasms NCT00447473

1 Formulare  
Criteria
Beschreibung

Criteria

testosterone < 50 ng/dl. patients must continue primary androgen deprivation with an lhrh analogue if they have not undergone orchiectomy.
Beschreibung

testosterone, androgen deprivation

Datentyp

boolean

Alias
UMLS CUI [1]
C0039601
UMLS CUI [2]
C0279492
progressive disease after androgen deprivation.
Beschreibung

progressive disease after androgen deprivation

Datentyp

boolean

Alias
UMLS CUI [1,1]
C1335499
UMLS CUI [1,2]
C0279492
patients who are receiving an antiandrogen as part of primary androgen ablation must demonstrate disease progression following discontinuation of antiandrogen.
Beschreibung

antiandrogen discontinuation disease progression

Datentyp

boolean

Alias
UMLS CUI [1,1]
C0002842
UMLS CUI [1,2]
C0457454
UMLS CUI [1,3]
C0242656
karnofsky performance status ≥ 60%.
Beschreibung

karnofsky performance status

Datentyp

boolean

Alias
UMLS CUI [1]
C0206065
one prior taxane based chemotherapy for prostate cancer. no more than two prior systemic therapies. at least four weeks have lapsed since prior therapy.
Beschreibung

prostate cancer taxane based chemotherapy

Datentyp

boolean

Alias
UMLS CUI [1,1]
C0600139
UMLS CUI [1,2]
C0392920
UMLS CUI [1,3]
C3541958
patients may have had prior ketoconazole, aminoglutethimide or corticosteroids for treatment of progressive prostate cancer.
Beschreibung

ketoconazole, aminoglutethimide, corticosteroids

Datentyp

boolean

Alias
UMLS CUI [1]
C0022625
UMLS CUI [2]
C0002555
UMLS CUI [3]
C0001617
patients receiving any other hormonal therapy, including any dose of megestrol acetate (megace), proscar (finasteride), any herbal product known to decrease psa levels (e.g., saw palmetto and pc-spes), or any systemic corticosteroid must discontinue the agent for at least 4 weeks prior to enrollment. progressive disease must be documented after discontinuation of the hormonal therapy.
Beschreibung

hormonal therapy, progressive disease documentation

Datentyp

boolean

Alias
UMLS CUI [1]
C0279025
UMLS CUI [2,1]
C0677932
UMLS CUI [2,2]
C0920316
patients on stable doses of bisphosphonates that show subsequent tumor progression may continue on this medication; however, patients are not allowed to initiate bisphosphonate therapy within one month prior to starting therapy or throughout the study.
Beschreibung

bisphosphonates

Datentyp

boolean

Alias
UMLS CUI [1]
C0012544
liver function tests (alt, ast) less than 1.5 x upper limit of normal (uln). the bilirubin must be within normal limits.
Beschreibung

liver function

Datentyp

boolean

Alias
UMLS CUI [1,1]
C0232741
UMLS CUI [1,2]
C0201913
UMLS CUI [1,3]
C0201836
UMLS CUI [1,4]
C0201899
anc >1500/µl, platelet count > 100,00/µl, creatinine <1.5 x uln, hemoglobin > 8 mg/dl
Beschreibung

anc, platelet count, creatinine, hemoglobin

Datentyp

boolean

Alias
UMLS CUI [1]
C0948762
UMLS CUI [2]
C0005821
UMLS CUI [3]
C0201976
UMLS CUI [4]
C0019046
ejection fraction ≥45%.
Beschreibung

cardiac ejection fraction

Datentyp

boolean

Alias
UMLS CUI [1]
C0232174
Zum Seitenanfang zurückkehren

Ähnliche Modelle

Eligibility Prostatic Neoplasms NCT00447473

1 Formulare
Name
Typ
Description | Question | Decode (Coded Value)
Datentyp
Alias
Item Group
testosterone, androgen deprivation
Item
testosterone < 50 ng/dl. patients must continue primary androgen deprivation with an lhrh analogue if they have not undergone orchiectomy.
boolean
C0039601 (UMLS CUI [1])
C0279492 (UMLS CUI [2])
progressive disease after androgen deprivation
Item
progressive disease after androgen deprivation.
boolean
C1335499 (UMLS CUI [1,1])
C0279492 (UMLS CUI [1,2])
antiandrogen discontinuation disease progression
Item
patients who are receiving an antiandrogen as part of primary androgen ablation must demonstrate disease progression following discontinuation of antiandrogen.
boolean
C0002842 (UMLS CUI [1,1])
C0457454 (UMLS CUI [1,2])
C0242656 (UMLS CUI [1,3])
karnofsky performance status
Item
karnofsky performance status ≥ 60%.
boolean
C0206065 (UMLS CUI [1])
prostate cancer taxane based chemotherapy
Item
one prior taxane based chemotherapy for prostate cancer. no more than two prior systemic therapies. at least four weeks have lapsed since prior therapy.
boolean
C0600139 (UMLS CUI [1,1])
C0392920 (UMLS CUI [1,2])
C3541958 (UMLS CUI [1,3])
ketoconazole, aminoglutethimide, corticosteroids
Item
patients may have had prior ketoconazole, aminoglutethimide or corticosteroids for treatment of progressive prostate cancer.
boolean
C0022625 (UMLS CUI [1])
C0002555 (UMLS CUI [2])
C0001617 (UMLS CUI [3])
hormonal therapy, progressive disease documentation
Item
patients receiving any other hormonal therapy, including any dose of megestrol acetate (megace), proscar (finasteride), any herbal product known to decrease psa levels (e.g., saw palmetto and pc-spes), or any systemic corticosteroid must discontinue the agent for at least 4 weeks prior to enrollment. progressive disease must be documented after discontinuation of the hormonal therapy.
boolean
C0279025 (UMLS CUI [1])
C0677932 (UMLS CUI [2,1])
C0920316 (UMLS CUI [2,2])
bisphosphonates
Item
patients on stable doses of bisphosphonates that show subsequent tumor progression may continue on this medication; however, patients are not allowed to initiate bisphosphonate therapy within one month prior to starting therapy or throughout the study.
boolean
C0012544 (UMLS CUI [1])
liver function
Item
liver function tests (alt, ast) less than 1.5 x upper limit of normal (uln). the bilirubin must be within normal limits.
boolean
C0232741 (UMLS CUI [1,1])
C0201913 (UMLS CUI [1,2])
C0201836 (UMLS CUI [1,3])
C0201899 (UMLS CUI [1,4])
anc, platelet count, creatinine, hemoglobin
Item
anc >1500/µl, platelet count > 100,00/µl, creatinine <1.5 x uln, hemoglobin > 8 mg/dl
boolean
C0948762 (UMLS CUI [1])
C0005821 (UMLS CUI [2])
C0201976 (UMLS CUI [3])
C0019046 (UMLS CUI [4])
cardiac ejection fraction
Item
ejection fraction ≥45%.
boolean
C0232174 (UMLS CUI [1])
Zum Seitenanfang zurückkehren 

Kontakt

Benutzen Sie dieses Formular für Rückmeldungen, Fragen und Verbesserungsvorschläge.

Mit * gekennzeichnete Felder sind notwendig.

Hilfe

Benötigen Sie Hilfe bei der Suche? Um mehr Details zu erfahren und die Suche effektiver nutzen zu können schauen Sie sich doch das entsprechende Video auf unserer Tutorial Seite an.

Zum Video